Trials / Terminated
TerminatedNCT03359174
An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis
An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine whether a low dose of ATRA will improve laboratory tests of liver and bile duct inflammation in patients with PSC. The investigators will also look for changes to other blood tests which are related to inflammation, scarring, and the immune system.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | All-trans retinoic acid | Fixed low dose of ATRA 10 mg twice daily for 24 weeks. |
Timeline
- Start date
- 2018-05-29
- Primary completion
- 2020-12-01
- Completion
- 2021-01-01
- First posted
- 2017-12-02
- Last updated
- 2021-08-09
- Results posted
- 2021-08-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03359174. Inclusion in this directory is not an endorsement.